Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
British Journal of Cancer|March 18, 2010
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patientsC Montagut, M Iglesias, M Arumi, et al.
British Journal of Cancer|September 30, 2016
FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancerL Marzi, E Combes, N Vié, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2017
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patientsJ Vidal, L Muinelo, A Dalmases, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialA Abad, E Martínez-Balibrea, J M Viéitez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2022
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupJ Pascual, G Attard, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapyJ Vidal, B Bellosillo, C Santos Vivas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancerJ Grasselli, E Elez, G Caratù, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2017
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access ProgramM González-Cao, A Arance, J M Piulats, et al.
ESMO Open|September 4, 2025
Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B studyV Martelli, J Vidal, J Gibert, et al.
ESMO Open|July 17, 2025
A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancerC Prieto-de-la-Lastra, J A Carbonell-Asins, A Bueno, et al.
Pageof 2